New therapies for type 2 diabetes based on glucagon-like peptide 1

  • Cleveland Clinic Journal of Medicine
  • April 2006,
  • 73
  • (4)
  • 382-389;

ABSTRACT

Cells in the gastrointestinal tract secrete several hormones that stimulate insulin secretion, one of which is glucagon-like peptide (GLP-1). Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes. One such compound, exenatide (Byetta), has recently become available, and others are in clinical development.

View Abstract
Loading
  • Print
  • Download PDF
  • Article Alerts
  • Email Article
  • Citation Tools
  • Share

Jump to section